c-Abl Inhibition Delays Motor Neuron Degeneration in the G93A Mouse, an Animal Model of Amyotrophic Lateral Sclerosis

PLoS ONE

Volumn 7, Issue 9, 2012, Pages

  Katsumata, Ryu ^a   Ishigaki, Shinsuke ^a,b,c   Katsuno, Masahisa ^a   Kawai, Kaori ^a   Sone, Jun ^a   Huang, Zhe ^a   Adachi, Hiroaki ^a   Tanaka, Fumiaki ^a   Urano, Fumihiko ^b   Sobue, Gen ^a,c  

^a NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^c JAPAN SCIENCE AND TECHNOLOGY AGENCY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ABELSON KINASE; CASPASE 3; COPPER ZINC SUPEROXIDE DISMUTASE; DASATINIB;

ABELSON KINASE GENE; ADULT; AGED; AMYOTROPHIC LATERAL SCLEROSIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CADAVER; CASE REPORT; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOTOXICITY; DOSE RESPONSE; DRUG EFFECT; DRUG MECHANISM; DRUG MEGADOSE; ENZYME ACTIVATION; ENZYME INACTIVATION; FEMALE; GENE; GENE ACTIVATION; GENE EXPRESSION REGULATION; GENE MUTATION; GENE OVEREXPRESSION; GENE REPRESSION; GENE TARGETING; HUMAN; HUMAN CELL; HUMAN TISSUE; LUMBAR SPINE; MALE; MOUSE; MUSCLE INNERVATION; NEUROMUSCULAR SYNAPSE; NEUROPROTECTION; NONHUMAN; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SPINAL CORD MOTONEURON; SURVIVAL RATE; TRANSGENIC MOUSE; UPREGULATION;

AMYOTROPHIC LATERAL SCLEROSIS; ANIMALS; DISEASE MODELS, ANIMAL; MICE; MOTOR NEURONS; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-ABL; PYRIMIDINES; SUPEROXIDE DISMUTASE; THIAZOLES;

ANIMALIA; MUS; MUS MUSCULUS;

EID: 84866661616     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0046185     Document Type: Article

References (58)

1. Tyler HR, Shefner J (1991) Amyotrophic lateral sclerosis. In: Vinken PJ, Bruyn GW, Klawans HL, editors. Handbook of Clinical Neurology. Amsterdam: Elsevier Science Publishers BV. pp. 169-215.
2. Emery A, Holloway S (1982) Familial motor neuron diseases. In: Rowland L, editor. Human Motor Neuron Diseases. New York: Raven Press Ltd. pp. 139-147.
3. Rosen DR, Siddique T, Patterson D, Figlewicz DA, Sapp P, et al. (1993) Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis. Nature 362: 59-62.
4. Martin LJ, Liu Z, Chen K, Price AC, Pan Y, et al. (2007) Motor neuron degeneration in amyotrophic lateral sclerosis mutant superoxide dismutase-1 transgenic mice: mechanisms of mitochondriopathy and cell death. J Comp Neurol 500: 20-46.
5. Bruijn LI, Houseweart MK, Kato S, Anderson KL, Anderson SD, et al. (1998) Aggregation and motor neuron toxicity of an ALS-linked SOD1 mutant independent from wild-type SOD1. Science 281: 1851-1854.
6. Boillee S, Vande Velde C, Cleveland DW, (2006) ALS: a disease of motor neurons and their nonneuronal neighbors. Neuron 52: 39-59.
7. Julien JP, (2001) Amyotrophic lateral sclerosis. unfolding the toxicity of the misfolded. Cell 104: 581-591.
8. Kabashi E, Durham HD, (2006) Failure of protein quality control in amyotrophic lateral sclerosis. Biochim Biophys Acta 1762: 1038-1050.
9. Cassina P, Cassina A, Pehar M, Castellanos R, Gandelman M, et al. (2008) Mitochondrial dysfunction in SOD1G93A-bearing astrocytes promotes motor neuron degeneration: prevention by mitochondrial-targeted antioxidants. J Neurosci 28: 4115-4122.
10. Jiang YM, Yamamoto M, Kobayashi Y, Yoshihara T, Liang Y, et al. (2005) Gene expression profile of spinal motor neurons in sporadic amyotrophic lateral sclerosis. Ann Neurol 57: 236-251.
11. Jiang YM, Yamamoto M, Tanaka F, Ishigaki S, Katsuno M, et al. (2007) Gene expressions specifically detected in motor neurons (dynactin 1, early growth response 3, acetyl-CoA transporter, death receptor 5, and cyclin C) differentially correlate to pathologic markers in sporadic amyotrophic lateral sclerosis. J Neuropathol Exp Neurol 66: 617-627.
12. Wang JY, Ledley F, Goff S, Lee R, Groner Y, et al. (1984) The mouse c-abl locus: molecular cloning and characterization. Cell 36: 349-356.
13. Nowell PC, Hungerford DA, (1960) A minute chromosome in human chronic granulocytic leukemia. Science 132: 1488-1501.
14. Fainstein E, Marcelle C, Rosner A, Canaani E, Gale RP, et al. (1987) A new fused transcript in Philadelphia chromosome positive acute lymphocytic leukaemia. Nature 330: 386-388.
15. Brasher BB, Van Etten RA, (2000) c-Abl has high intrinsic tyrosine kinase activity that is stimulated by mutation of the Src homology 3 domain and by autophosphorylation at two distinct regulatory tyrosines. J Biol Chem 275: 35631-35637.
16. Sirvent A, Benistant C, Roche S, (2008) Cytoplasmic signalling by the c-Abl tyrosine kinase in normal and cancer cells. Biol Cell 100: 617-631.
17. Pendergast AM, (2002) The Abl family kinases: mechanisms of regulation and signaling. Adv Cancer Res 85: 51-100.
18. Zandy NL, Playford M, Pendergast AM, (2007) Abl tyrosine kinases regulate cell-cell adhesion through Rho GTPases. Proc Natl Acad Sci U S A 104: 17686-17691.
19. Gu JJ, Ryu JR, Pendergast AM, (2009) Abl tyrosine kinases in T-cell signaling. Immunol Rev 228: 170-183.
20. Wang JY, (2000) Regulation of cell death by the Abl tyrosine kinase. Oncogene 19: 5643-5650.
21. Yuan ZM, Shioya H, Ishiko T, Sun X, Gu J, et al. (1999) p73 is regulated by tyrosine kinase c-Abl in the apoptotic response to DNA damage. Nature 399: 814-817.
22. Wang JY, Ki SW, (2001) Choosing between growth arrest and apoptosis through the retinoblastoma tumour suppressor protein, Abl and p73. Biochem Soc Trans 29: 666-673.
23. Lu W, Finnis S, Xiang C, Lee HK, Markowitz Y, et al. (2007) Tyrosine 311 is phosphorylated by c-Abl and promotes the apoptotic effect of PKCdelta in glioma cells. Biochem Biophys Res Commun 352: 431-436.
24. Chen TC, Lai YK, Yu CK, Juang JL, (2007) Enterovirus 71 triggering of neuronal apoptosis through activation of Abl-Cdk5 signalling. Cell Microbiol 9: 2676-2688.
25. Lee JH, Jeong MW, Kim W, Choi YH, Kim KT, (2008) Cooperative roles of c-Abl and Cdk5 in regulation of p53 in response to oxidative stress. J Biol Chem 283: 19826-19835.
26. Zukerberg LR, Patrick GN, Nikolic M, Humbert S, Wu CL, et al. (2000) Cables links Cdk5 and c-Abl and facilitates Cdk5 tyrosine phosphorylation, kinase upregulation, and neurite outgrowth. Neuron 26: 633-646.
27. Koleske AJ, Gifford AM, Scott ML, Nee M, Bronson RT, et al. (1998) Essential roles for the Abl and Arg tyrosine kinases in neurulation. Neuron 21: 1259-1272.
28. Cancino GI, Toledo EM, Leal NR, Hernandez DE, Yevenes LF, et al. (2008) STI571 prevents apoptosis, tau phosphorylation and behavioural impairments induced by Alzheimer's beta-amyloid deposits. Brain 131: 2425-2442.
29. Alvarez AR, Sandoval PC, Leal NR, Castro PU, Kosik KS, (2004) Activation of the neuronal c-Abl tyrosine kinase by amyloid-beta-peptide and reactive oxygen species. Neurobiol Dis 17: 326-336.
30. Cashman NR, Durham HD, Blusztajn JK, Oda K, Tabira T, et al. (1992) Neuroblastoma x spinal cord (NSC) hybrid cell lines resemble developing motor neurons. Dev Dyn 194: 209-221.
31. Lombardo LJ, Lee FY, Chen P, Norris D, Barrish JC, et al. (2004) Discovery of N-(2-chloro-6-methyl- phenyl)-2-(6-(4-(2-hydroxyethyl)- piperazin-1-yl)-2-methylpyrimidin-4-ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays. J Med Chem 47: 6658-6661.
32. Blake RA, Broome MA, Liu X, Wu J, Gishizky M, et al. (2000) SU6656, a selective src family kinase inhibitor, used to probe growth factor signaling. Mol Cell Biol 20: 9018-9027.
33. Alvarez AR, Klein A, Castro J, Cancino GI, Amigo J, et al. (2008) Imatinib therapy blocks cerebellar apoptosis and improves neurological symptoms in a mouse model of Niemann-Pick type C disease. FASEB J 22: 3617-3627.
34. Dangond F, Hwang D, Camelo S, Pasinelli P, Frosch MP, et al. (2004) Molecular signature of late-stage human ALS revealed by expression profiling of postmortem spinal cord gray matter. Physiol Genomics 16: 229-239.
35. Martin LJ, (2010) Mitochondrial and cell death mechanisms in neurodegenerative diseases. Pharmaceuticals (Basel) 3: 839-915.
36. An X, Tiwari AK, Sun Y, Ding PR, Ashby CR Jr, et al. (2010) BCR-ABL tyrosine kinase inhibitors in the treatment of Philadelphia chromosome positive chronic myeloid leukemia: a review. Leuk Res 34: 1255-1268.
37. Agrawal M, Garg RJ, Kantarjian H, Cortes J, (2010) Chronic myeloid leukemia in the tyrosine kinase inhibitor era: what is the "best" therapy? Curr Oncol Rep 12: 302-313.
38. Braconi C, Bracci R, Cellerino R, (2008) Molecular targets in Gastrointestinal Stromal Tumors (GIST) therapy. Curr Cancer Drug Targets 8: 359-366.
39. Isobe Y, Sugimoto K, Masuda A, Hamano Y, Oshimi K, (2009) Central nervous system is a sanctuary site for chronic myelogenous leukaemia treated with imatinib mesylate. Intern Med J 39: 408-411.
40. Aichberger KJ, Herndlhofer S, Agis H, Sperr WR, Esterbauer H, et al. (2007) Liposomal cytarabine for treatment of myeloid central nervous system relapse in chronic myeloid leukaemia occurring during imatinib therapy. Eur J Clin Invest 37: 808-813.
41. Simpson E, O'Brien SG, Reilly JT, (2006) Extramedullary blast crises in CML patients in complete hematological remission treated with imatinib mesylate. Clin Lab Haematol 28: 215-216.
42. Matsuda M, Morita Y, Shimada T, Miyatake J, Hirase C, et al. (2005) Extramedullary blast crisis derived from 2 different clones in the central nervous system and neck during complete cytogenetic remission of chronic myelogenous leukemia treated with imatinib mesylate. Int J Hematol 81: 307-309.
43. Rajappa S, Uppin SG, Raghunadharao D, Rao IS, Surath A, (2004) Isolated central nervous system blast crisis in chronic myeloid leukemia. Hematol Oncol 22: 179-181.
44. Bujassoum S, Rifkind J, Lipton JH, (2004) Isolated central nervous system relapse in lymphoid blast crisis chronic myeloid leukemia and acute lymphoblastic leukemia in patients on imatinib therapy. Leuk Lymphoma 45: 401-403.
45. Porkka K, Koskenvesa P, Lundan T, Rimpilainen J, Mustjoki S, et al. (2008) Dasatinib crosses the blood-brain barrier and is an efficient therapy for central nervous system Philadelphia chromosome-positive leukemia. Blood 112: 1005-1012.
46. Ito Y, Pandey P, Mishra N, Kumar S, Narula N, et al. (2001) Targeting of the c-Abl tyrosine kinase to mitochondria in endoplasmic reticulum stress-induced apoptosis. Mol Cell Biol 21: 6233-6242.
47. Gonfloni S, (2010) DNA damage stress response in germ cells: role of c-Abl and clinical implications. Oncogene 29: 6193-6202.
48. Kanning KC, Kaplan A, Henderson CE, (2010) Motor neuron diversity in development and disease. Annu Rev Neurosci 33: 409-440.
49. Vila M, Przedborski S, (2003) Targeting programmed cell death in neurodegenerative diseases. Nat Rev Neurosci 4: 365-375.
50. Ludolph AC, Bendotti C, Blaugrund E, Hengerer B, Loffler JP, et al. (2007) Guidelines for the preclinical in vivo evaluation of pharmacological active drugs for ALS/MND: report on the 142nd ENMC international workshop. Amyotroph Lateral Scler 8: 217-223.
51. Inoue H, Tsukita K, Iwasato T, Suzuki Y, Tomioka M, et al. (2003) The crucial role of caspase-9 in the disease progression of a transgenic ALS mouse model. EMBO J 22: 6665-6674.
52. Campeau E, Ruhl VE, Rodier F, Smith CL, Rahmberg BL, et al. (2009) A versatile viral system for expression and depletion of proteins in mammalian cells. PLoS One 4: e6529.
53. Gurney ME, Pu H, Chiu AY, Dal Canto MC, Polchow CY, et al. (1994) Motor neuron degeneration in mice that express a human Cu,Zn superoxide dismutase mutation. Science 264: 1772-1775.
54. Adachi H, Kume A, Li M, Nakagomi Y, Niwa H, et al. (2001) Transgenic mice with an expanded CAG repeat controlled by the human AR promoter show polyglutamine nuclear inclusions and neuronal dysfunction without neuronal cell death. Hum Mol Genet 10: 1039-1048.
55. Adachi H, Waza M, Tokui K, Katsuno M, Minamiyama M, et al. (2007) CHIP overexpression reduces mutant androgen receptor protein and ameliorates phenotypes of the spinal and bulbar muscular atrophy transgenic mouse model. J Neurosci 27: 5115-5126.
56. Minamiyama M, Katsuno M, Adachi H, Waza M, Sang C, et al. (2004) Sodium butyrate ameliorates phenotypic expression in a transgenic mouse model of spinal and bulbar muscular atrophy. Hum Mol Genet 13: 1183-1192.
57. Katsuno M, Adachi H, Kume A, Li M, Nakagomi Y, et al. (2002) Testosterone reduction prevents phenotypic expression in a transgenic mouse model of spinal and bulbar muscular atrophy. Neuron 35: 843-854.
58. Ishigaki S, Liang Y, Yamamoto M, Niwa J, Ando Y, et al. (2002) X-Linked inhibitor of apoptosis protein is involved in mutant SOD1-mediated neuronal degeneration. J Neurochem 82: 576-584.